{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:46:08Z","timestamp":1763048768355,"version":"3.45.0"},"reference-count":26,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443414435"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.mcb.2025.06.001","type":"book-chapter","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:43:42Z","timestamp":1754599422000},"page":"273-285","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy and cancer vaccine development"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.mcb.2025.06.001_bib1","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1038\/s41467-024-49189-x","article-title":"TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer","volume":"15","author":"Anandhan","year":"2024","journal-title":"Nature Communications"},{"key":"10.1016\/bs.mcb.2025.06.001_bib2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00262-012-1201-0","article-title":"Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer","volume":"61","author":"Andersson","year":"2012","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"key":"10.1016\/bs.mcb.2025.06.001_bib3","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","article-title":"Organoid models of human and mouse ductal pancreatic cancer","volume":"160","author":"Boj","year":"2015","journal-title":"Cell"},{"key":"10.1016\/bs.mcb.2025.06.001_bib4","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.jss.2012.07.029","article-title":"Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer","volume":"181","author":"Hanagiri","year":"2013","journal-title":"The Journal of Surgical Research"},{"key":"10.1016\/bs.mcb.2025.06.001_bib5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.4161\/onci.21056","article-title":"Expression of mhc class I on breast cancer cells correlates inversely with her2 expression","volume":"1","author":"Inoue","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.mcb.2025.06.001_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"82","key":"10.1016\/bs.mcb.2025.06.001_bib7","doi-asserted-by":"crossref","DOI":"10.3791\/50181-v","article-title":"An orthotopic bladder cancer model for gene delivery studies","author":"Kasman","year":"2013","journal-title":"Journal of Visualized Experiments"},{"key":"10.1016\/bs.mcb.2025.06.001_bib8","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s00262-022-03202-8","article-title":"First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience","volume":"71","author":"Kreutmair","year":"2022","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"key":"10.1016\/bs.mcb.2025.06.001_bib9","doi-asserted-by":"crossref","unstructured":"Labanieh, L., & Mackall, C. L. CAR immune cells: Design principles, resistance and the next generation. Nature, 614.","DOI":"10.1038\/s41586-023-05707-3"},{"key":"10.1016\/bs.mcb.2025.06.001_bib10","article-title":"CD19 targeted chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","author":"Maude","year":"2015","journal-title":"The American Society of Hematology"},{"key":"10.1016\/bs.mcb.2025.06.001_bib11","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1158\/1078-0432.CCR-04-2146","article-title":"Defects in the human leukocyte antigen class I antigen-processing machinery in head and neck squamous cell carcinoma: Association with clinical outcome","volume":"11","author":"Meissner","year":"2005","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.mcb.2025.06.001_bib12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small. Cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.mcb.2025.06.001_bib13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.mcb.2025.06.001_bib14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/bs.mcb.2025.06.001_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-022-00433-9","article-title":"Neoantigen cancer vaccine augments anti-CTLA-4 efficacy","volume":"7","author":"Salvatori","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/bs.mcb.2025.06.001_bib16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1089\/hum.2016.097","article-title":"Chimeric antigen receptor T cell therapy targeting CD19-positive leukemia and lymphoma in the context of stem cell transplantation","volume":"27","author":"Schubert","year":"2016","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.mcb.2025.06.001_bib17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/gut.2009.194472","article-title":"Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer","volume":"59","author":"Simpson","year":"2010","journal-title":"Gut"},{"key":"10.1016\/bs.mcb.2025.06.001_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0022-3468(90)90375-J","article-title":"The relationship of class I MHC antigen expression to stage IV-S disease and survival in neuroblastoma","volume":"25","author":"Squire","year":"1990","journal-title":"Journal of Pediatric Surgery"},{"key":"10.1016\/bs.mcb.2025.06.001_bib19","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.3390\/ijms20246223","article-title":"Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy","volume":"20","author":"Stock","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.mcb.2025.06.001_bib20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1158\/2326-6066.CIR-13-0180","article-title":"Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases","volume":"2","author":"Turcotte","year":"2014","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.mcb.2025.06.001_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ijc.23543","article-title":"Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression","volume":"123","author":"Van Houdt","year":"2008","journal-title":"International Journal of Cancer. Journal International du Cancer"},{"key":"10.1016\/bs.mcb.2025.06.001_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40425-018-0333-y","article-title":"Prime-boost vaccination targeting prostatic acid phospha- tase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine","volume":"6","author":"Wargowski","year":"2018","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.mcb.2025.06.001_bib23","unstructured":"Watanabe, N., Mo, F.,\u00a0 McKenna, M. K. Impact of manufacturing procedures on CAR T cell functionality."},{"key":"10.1016\/bs.mcb.2025.06.001_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ijc.21303","article-title":"Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis","volume":"118","author":"Watson","year":"2006","journal-title":"International Journal of Cancer. Journal International du Cancer"},{"issue":"3","key":"10.1016\/bs.mcb.2025.06.001_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/vaccines1030225","article-title":"Vector design for improved DNA vaccine efficacy, safety and production","volume":"1","author":"Williams","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/bs.mcb.2025.06.001_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: Promising targets for cancer therapy","author":"Xie","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"}],"container-title":["Methods in Cell Biology","Advanced Cancer Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X25001335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X25001335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:42:20Z","timestamp":1763048540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091679X25001335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443414435"],"references-count":26,"URL":"https:\/\/doi.org\/10.1016\/bs.mcb.2025.06.001","relation":{},"ISSN":["0091-679X"],"issn-type":[{"type":"print","value":"0091-679X"}],"subject":[],"published":{"date-parts":[[2025]]}}}